The company has received a letter from the US Food and Drug Administration (USFDA) classifying the inspection conducted at its Goa facility between January 28 to February 8 as Official Action Indicated (OAI), Lupin said in a regulatory filing.Lupin#39;s Goa facility may face regulatory action, says USFDA
The company has received a letter from the US Food and Drug Administration (USFDA) classifying the inspection conducted at its Goa facility between January 28 to February 8 as Official Action Indicated (OAI), Lupin said in a regulatory filing.
Subscribe to:
Post Comments (Atom)
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
-
In July, HCL Technologies had announced a Rs 4,000 crore buyback programme for FY19 at a price of Rs 1,100 per equity share.
No comments:
Post a Comment